Cedars-Sinai Medical Center - UCLA School of Medicine
Samuel Oschin Comprehensive Cancer Institute
Los Angeles, CA
Not currently accepting
Iberdomide vs. Observation Post Ide-Cel CAR-T
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
- CELMoD
- Maintenance
- Randomization
- Phase 2
Accepting patients
Etentamig for Newly Diagnosed Patients
Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Bispecific Antibody
- CD3
- BCMA
- Randomization
- Phase 2/3
Accepting patients
CERVINO
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
Accepting patients
QXL138AM
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Masked Immunocytokine (MIC)
- CD138
- Phase 1
Accepting patients
Autologous Stem Cell Transplant Post CAR-T
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
- Autologous Stem Cell Transplant
- CAR T Cell
- BCMA
- Phase 1
1 hidden based on your filters.Show All